[Newly developed muscle relaxants].
Fukushima
K
K
D001279:Atracurium / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D000077590:Mivacurium; D009466:Neuromuscular Blocking Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D010197:Pancuronium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D013997:Time Factors; D014403:Tubocurarine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology; D014673:Vecuronium Bromide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology
D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D003473:Neuromuscular Nondepolarizing Agents; D001279:Atracurium; D000077590:Mivacurium; D014673:Vecuronium Bromide; D010197:Pancuronium; C049429:doxacurium; C101584:cisatracurium; D014403:Tubocurarine